Aman Mehta, the third generation of Torrent Group's founder Mehta family, has been appointed the Managing Director of the conglomerate's flagship Torrent Pharmaceuticals, effective August 1, 2025.

He was appointed as a Director on the board of Torrent Pharma in August 2022, marking the beginning of the third-generation leadership taking charge at the company.

"We are pleased to share that as part of our long-term strategic vision and succession planning, the Board has approved the appointment of Aman Mehta as Managing Director, effective August 1, 2025," Torrent Pharma said in a statement.

"He has been Director at Torrent Pharma since August 2022 and heads the India and RoW Business. His key achievement has been the successful integration of the Unichem acquisition, which has created significant value for the company," his profile on the company website says.

Aman, 33, was primarily involved in the India business, Torrent's largest revenue contributor. He holds a Bachelor of Economics degree from Boston University and an MBA from Columbia University, New York. He joined the Torrent Group in 2013.

He played an instrumental role in integrating the Unichem acquisition and the strategic identification and integration of Curatio Healthcare, both of which delivered substantial value and synergies to the company.

Starting with pharmaceuticals, Torrent made a foray into the power sector in 1996 and into the gas business in 2018. When founder U N Mehta passed away in 1998, Sudhir, his eldest son, took charge as chairman of Torrent Pharma and Torrent Power. The group has since diversified into adjacencies - hospitals and diagnostics in healthcare and renewables, thermal, pumped hydro storage (PHS) and green hydrogen in energy.

Since he was appointed as full-time Director, he has continued to make a significant impact on India's business growth and transformation journey. His contribution includes market share expansion through organic growth and strategic in-licensing. Making a significant contribution to cardiac and diabetes medicines, with a significant improvement in performance and ranking and the launch of a consumer health division.

Under his leadership, R&D has been more sharply aligned with business strategy and a focus on differentiated product development and faster execution of critical projects. His inputs have helped drive operational excellence initiatives across manufacturing and supply chain functions, leading to increased focus on productivity, cost efficiency, margins, and service levels.